Clinical trials: Non Erosive Reflux Disease
Gastroesophageal Reflux Disease
Efficacy of Pantoprazole in Patients Older Than 12 Years Who Have Symptoms of Non-Erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (eGERD)
The aim of the study was to evaluate the effect of 7 days treatment with Pantoprazole 40 mg and 20 mg on symptoms in patients with NERD (non-erosive reflux disease) or eGERD (erosive gastroesophageal reflux disease) in clinical…
- Trial name
- PANTHER (NCT00561730)
- Testing
- Pantoprazole
- Where
- 259 sites in Germany
- Volunteers
- 1,995 people
- Sponsor
- Nycomed
Non-erosive Reflux Disease, Diarrhea-Predominant Irritable Bowel Syndrome
Efficacy and Safety of WPQW Granule for Overlap of NERD and IBS-D
Non-erosive reflux disease（NERD）and Diarrhea-Predominant Irritable Bowel Syndrome（IBS-D）are both the common refractory gastrointestinal diseases.
- Trial name
- NCT05369884
- Testing
- WPQW granule, WPQW granule simulant
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-erosive Gastroesophageal Reflux Disease, Functional Dyspepsia
Functional Gastrointestinal Disorder Screening Program - A Randomized Controlled Trial
Background: Functional gastrointestinal disorder (FGID) is the most common gastrointestinal disease in daily clinical practice. The disease is symptomatic but has no identifiable cause by standard diagnostic tests such as…
- Conditions
- Non-erosive Gastroesophageal Reflux Disease, Functional Dyspepsia, Irritable Bowel Syndrome
- Trial name
- FGISP-RCT (NCT01047800)
- Testing
- Counseling
- Where
- Hong Kong
- Volunteers
- 200 people
- Sponsor
- Chinese University of Hong Kong
Non-erosive Reflux Disease
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of LXI-15028 in Non-erosive Reflux Disease in Chinese Patients for 4 Weeks
This is one multi-center, randomized, double-blind, parallel-group, placebo controlled Phase III clinical study to evaluate the efficacy and safety of LXI-15028 50 mg in treatment of non-erosive reflux disease in Chinese patients…
- Trial name
- NCT03591653
- Testing
- LXI-15028
- Where
- China
- Volunteers
- 291 people
- Sponsor
- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Non-erosive Reflux Disease, Reflux Disease, Gastro-Esophageal
Evaluation of the Efficacy and Safety of Eolo in Patients With NERD
Background: Non-erosive reflux disease (NERD) is a prevalent subtype of gastroesophageal reflux disease (GERD), often inadequately managed with proton pump inhibitors (PPIs) alone.
- Conditions
- Non-erosive Reflux Disease, Reflux Disease, Gastro-Esophageal, Nutraceutical
- Trial name
- NCT07041060
- Testing
- EOLO, PPI (proton pump inhibitor), Group C: Eolo
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Bologna
Reflux Esophagitis (RE), Non-erosive Reflux Disease (NERD)
Analysis of GERD Symptoms Using Gastroesophageal Reflux Impact Score Questionnaire for Quality of Life
Even the patients complain GERD symptoms such as heartburn and acid regurgitation the final diagnosis could be reflux esophagitis (RE), non-erosive reflux disease (NERD) and even functional heartburn (FH).
- Conditions
- Reflux Esophagitis (RE), Non-erosive Reflux Disease (NERD), Functional Heartburn (FH)
- Trial name
- NCT01536080
- Where
- South Korea
- Volunteers
- 207 people
- Sponsor
- Seoul National University Bundang Hospital
Healthy Volunteers
A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants
The primary objective of this study is to assess the bioavailability (BA) of a single oral dose of two vonoprazan orally disintegrating tablet formulations (ODT-1 or ODT-2) administered without water or mixed with water and…
- Trial name
- NCT06831344
- Testing
- Vonoprazan ODT-1 or ODT-2 without Water, Vonoprazan ODT-1 or ODT-2 with Water, Vonoprazan (Reference)
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Phathom Pharmaceuticals, Inc.
Gastroesophageal Reflux Disease
Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD)
To understand the dose-response characteristics of PF-00885706 for efficacy in terms of symptomatic relief when used as add-on treatment to esomeprazole 20mg (standard proton pump inhibitor [PPI] treatment), in subjects with…
- Trial name
- NCT00730665
- Testing
- PF-00885706, Esomeprazole
- Where
- 38 sites in Belgium, Brazil and 5 more
- Volunteers
- 81 people
- Sponsor
- Pfizer
Gastroesophageal Reflux
A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn
The purpose of this study is to determine whether Dexlansoprazole once daily (QD) is effective in treating patients with night heartburn.
- Trial name
- NCT00627016
- Testing
- Dexlansoprazole
- Where
- 43 sites in United States
- Volunteers
- 305 people
- Sponsor
- Takeda
Erosive Reflux Disease, Non-erosive Reflux Disease
Predictors of Proton Pump Inhibitor Response in Gastroesophageal Reflux Disease Patients
Proton pump inhibitor (PPI) is widely used in patients with gastroesophageal reflux disease (GERD), however, some patients fail to respond to PPI therapy.
- Conditions
- Erosive Reflux Disease, Non-erosive Reflux Disease, Functional Heartburn
- Trial name
- NCT01797939
- Where
- South Korea
- Volunteers
- 197 people
- Sponsor
- Seoul National University Bundang Hospital
Non-erosive Reflux Disease
A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population
The purpose of this study is to investigate the pharmacodynamic effect of omeprazole n a Japanese non-erosive reflux disease population
- Trial name
- NCT00259051
- Testing
- Omeprazole
- Where
- 13 sites in Japan
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Non Erosive Reflux Disease, Chronic Gastritis
Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients
To compare the symptom control rate between 8 weeks esomeprazole treatment regimen group and 2 weeks esomeprazole treatment regimen group in co-diagnosed NERD and chronic gastritis patients, as evaluated by GerdQ after 24 weeks…
- Trial name
- NCT01119768
- Testing
- Esomeprazole
- Where
- 8 sites in China
- Volunteers
- 305 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Study to Evaluate the Efficacy and Safety of FEXUCLUE Tablet
This observational study is a large-scale, prospective, and multi-institutional observational study. Patients from 19 to 75 years of age, will take a self-assessment (PRO) during the study period before and after administration…
- Trial name
- NCT05886933
- Testing
- Fexuprazan Hydrochloride
- Where
- South Korea
- Volunteers
- 9,846 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Non-erosive Gatroesophageal Reflux Disease
Treatment Response of Maintenance Dose of Proton Pump Inhibitor in Patients With Nonerosive Gatroesophageal Reflux Disease
For ERD(erosive reflux disease), which pathogenesis is mainly the acid reflux mechanism, primary treatment is therefore PPI. However, NERD(non-erosive reflux disease) is much more complex than ERD and there are more factors…
- Trial name
- NCT03436914
- Testing
- PPI
- Where
- South Korea
- Volunteers
- 62 people
- Sponsor
- Yonsei University
Erosive Esophagitis
Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD)
A randomized, double-blind, double-dummy, active comparator, multi-centers, non-inferiority design clinical trial to assess the efficacy and safety of YYD601 in ERD patients (phase 3).
- Trial name
- NCT03943992
- Testing
- YYD601 40mg, Nexium 40mg
- Where
- South Korea
- Volunteers
- 170 people
- Sponsor
- Yooyoung Pharmaceutical Co., Ltd.
Non-erosive Reflux Disease, Non-Erosive Gastro-Esophageal Reflux Disease
Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD)
This study is designed to determine the efficacy and safety of DWP14012 compared to a placebo following a once-daily oral dose of DWP14012 at 20 mg, 40 mg, or placebo for 4 weeks in patients with NERD.
- Conditions
- Non-erosive Reflux Disease, Non-Erosive Gastro-Esophageal Reflux Disease, Non-Erosive Esophageal Reflux Disease
- Trial name
- NCT06121830
- Testing
- DWP14012 20mg, DWP14012 40mg
- Where
- South Korea
- Volunteers
- 324 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Gastroesophageal Reflux Disease, Non-erosive Reflux Disease
The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511)
The aim of the study is to compare two different endpoint measures: heartburn as assessed by the physicians versus gastroesophageal reflux disease (GERD)-related symptoms as assessed by the patient using the ReQuest™…
- Trial name
- NCT00449813
- Testing
- Pantoprazole
- Where
- 15 sites in Netherlands, Switzerland
- Volunteers
- 40 people
- Sponsor
- Takeda
Non-erosive Reflux Disease, Barrett's Esophagus
The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients
Gastroesophageal reflux disease(GERD) mainly related to the reflux of stomach content induced by the dysfunction of lower esophageal sphincter.
- Trial name
- NCT02149914
- Testing
- Ryodoraku, ANSWatch, UGI endoscopy
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Taichung Tzu Chi Hospital
Gastroesophageal Reflux
Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Non-erosive Reflux or Gastroesophageal Reflux Disease (BY1023/DE-004)
The aim of the study is to evaluate the effect of pantoprazole on fast symptom reduction in hospitalized patients with NERD (non-erosive reflux disease) or GERD (gastroesophageal reflux disease, Los Angeles [LA] Grade A-D).
- Trial name
- NCT00326027
- Testing
- Pantoprazole
- Where
- 35 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Nycomed
Gastroesophageal Reflux Disease
Maintenance Intermittent Therapy for Symptomatic GERD Patients
The purpose of this study to determine the efficacy of 20 mg of rabeprazole given as a maintenance intermittent therapy following acute treatment for Symptomatic Gastroesophageal Reflux Disease (s-GERD).
- Trial name
- NCT00165841
- Testing
- Rabeprazole 20 mg
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Eisai Inc.